

REMARKS

New claims 151 and 152 are supported by the specification as filed and therefore do not add new matter. Rituximab, ibritumomab tiuxetan and tositumomab have a common antigenic target, i.e., CD20, as disclosed at page 10, lines 13-14; page 13, lines 5-6; and page 14, lines 3-4. Entry of the new claims is requested.

The Examiner asserts that eighteen inventions are claimed in the application. Applicants elect the invention of Group I, Claims 1-6, 9-16, 17-19, 20, 21-71 and 149-150, without traverse. Applicants believe Claim 8 should be included in Group I, as it depends from Claim 6 which recites an antibody.

Applicants further elect the species rituximab for prosecution on the merits. Claims 1-6, 8-27, 48-55 and 149-152 read on the elected species.

The Examiner is requested to direct any questions concerning this response to the undersigned at the number shown below.

Respectfully submitted,

BY:



Donna R. Fugit, Ph.D.
Reg. No. 32,135

Genta Incorporated
Two Connell Drive
Berkeley Heights, NJ 07922
Tel. (908) 219-3195
Fax (908) 286-5982

Date: *Dec. 31, 2005*